In vitro studies demonstrated statistically significant (P <0.05) increases in free phenytoin after the addition of specific antibiotics to patients' sera and to phenytoin-supplemented sera from controls. Concentrations of free phenytoin in vivo, predicted by an equation we have found to be accurate for albumin concentrations 32 gIL, were consistently underestimated in patients receiving concomitant therapy with the antibiotics studied. The concentrations of free phenytoin decreased towards the predicted values when the antibiotic therapy was discontinued. We conclude that ceftriaxone, nafcillin, and sulfamethoxazole can displace phenytoin from the usual protein carriers found in serum, in vitro and in vivo. 
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Results and Discussion
In vitro experiments clearly demonstrated displacement of phenytoin from protein-binding sites by ceftriaxone and nafcillin at both concentrations of the antibiotics tested (Table 1) . In all cases the increase of free phenytoin (compared with that of controls) was statistically significant 
(10).
We also observed in vivo effects of drug-drug interactions in patients receiving phenytoin plus these phenytom-displacing antibiotics.
Concentrations of free phe-
nytoin were monitored in patients also receiving ceftriaxone, nafcillin, or sulfamethoxazole. Although data for the pre-antibiotic concentrations of free phenytoin were not available, we observed a decrease in the concentration of free phenytoin when nafcillin was discontinued. Concentrations of albumin in the sera of these patients remained unchanged throughout the period under investigation ( 
3.1
In vivo concentrations not obtainable.
100 CLINICALCHEMISTRY, Vol.37, No. 1, 1991 ismodulated by the measured albumin concentration, there is an increased need to monitor free phenytoin in hypo-albuminemic patients. To reduce the chance of phenytoin toxicity, we recommend monitoring free phenytoin in patients receiving any concomitant drug treatment that could competitively displace phenytoin from the serum protein carrier(s), especially in hypo-albuminemic patients.
